NZ550757A - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
NZ550757A
NZ550757A NZ550757A NZ55075705A NZ550757A NZ 550757 A NZ550757 A NZ 550757A NZ 550757 A NZ550757 A NZ 550757A NZ 55075705 A NZ55075705 A NZ 55075705A NZ 550757 A NZ550757 A NZ 550757A
Authority
NZ
New Zealand
Prior art keywords
alkyl
twice
unsubstituted
compound
imidazol
Prior art date
Application number
NZ550757A
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Grueneberg
Hauke Szillat
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ550757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NZ550757A publication Critical patent/NZ550757A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ550757A 2004-04-22 2005-04-07 Imidazole derivatives used as tafia inhibitors NZ550757A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren
EP05731221A EP1740569B1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
NZ550757A true NZ550757A (en) 2010-06-25

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ550757A NZ550757A (en) 2004-04-22 2005-04-07 Imidazole derivatives used as tafia inhibitors

Country Status (34)

Country Link
EP (2) EP1864979B1 (https=)
JP (1) JP4939401B2 (https=)
KR (1) KR101162047B1 (https=)
CN (1) CN100572376C (https=)
AR (1) AR053302A1 (https=)
AT (2) ATE386737T1 (https=)
AU (1) AU2005238144B2 (https=)
BR (1) BRPI0510159A (https=)
CA (1) CA2563401C (https=)
CR (1) CR8650A (https=)
CY (1) CY1108087T1 (https=)
DE (2) DE102004020186A1 (https=)
DK (1) DK1740569T3 (https=)
EC (1) ECSP066941A (https=)
ES (1) ES2299026T3 (https=)
HR (1) HRP20080099T3 (https=)
IL (1) IL178672A (https=)
MA (1) MA28543B1 (https=)
MY (1) MY140903A (https=)
NI (1) NI200600217A (https=)
NO (1) NO20065320L (https=)
NZ (1) NZ550757A (https=)
PE (1) PE20060172A1 (https=)
PL (1) PL1740569T3 (https=)
PT (1) PT1740569E (https=)
RS (1) RS50553B (https=)
RU (1) RU2375356C2 (https=)
SI (1) SI1740569T1 (https=)
TN (1) TNSN06341A1 (https=)
TW (1) TWI359016B (https=)
UA (1) UA87306C2 (https=)
UY (1) UY28868A1 (https=)
WO (1) WO2005105781A1 (https=)
ZA (1) ZA200607668B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150514T1 (hr) 2006-12-06 2015-09-11 Sanofi DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
MX2009008777A (es) * 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
SI2300462T1 (sl) 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
KR20120016651A (ko) * 2009-05-15 2012-02-24 사노피 Tafia의 억제제로서 유용한 화합물의 제조방법
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) * 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
DK2548871T3 (da) 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
MX2013004193A (es) * 2010-11-11 2013-06-05 Sanofi Sa Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
EP2782576B1 (en) 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782574B1 (de) 2011-11-25 2016-03-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT AGAINST INFLAMMATORY DARMER DISEASE
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104657A3 (en) * 1998-12-24 2002-07-29 Astellas Pharma Inc Chuo Ku Imidazole compounds and pharmaceutical compositions containing them
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
KR101162047B1 (ko) 2012-07-04
JP2007533672A (ja) 2007-11-22
TW200602325A (en) 2006-01-16
HRP20080099T3 (en) 2008-03-31
DK1740569T3 (da) 2008-06-02
TNSN06341A1 (en) 2008-02-22
MA28543B1 (fr) 2007-04-03
CN1950357A (zh) 2007-04-18
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
NI200600217A (es) 2008-06-17
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
CY1108087T1 (el) 2014-02-12
ATE523505T1 (de) 2011-09-15
IL178672A (en) 2011-08-31
IL178672A0 (en) 2007-02-11
DE502005002927D1 (de) 2008-04-03
SI1740569T1 (sl) 2008-06-30
AR053302A1 (es) 2007-05-02
AU2005238144B2 (en) 2010-08-26
RS50553B (sr) 2010-05-07
RU2375356C2 (ru) 2009-12-10
UA87306C2 (en) 2009-07-10
ES2299026T3 (es) 2008-05-16
CA2563401C (en) 2012-08-07
PT1740569E (pt) 2008-03-31
CR8650A (es) 2007-12-04
HK1101823A1 (zh) 2007-10-26
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
EP1864979A1 (de) 2007-12-12
EP1740569B1 (de) 2008-02-20
ZA200607668B (en) 2008-03-26
MY140903A (en) 2010-01-29
CN100572376C (zh) 2009-12-23
TWI359016B (en) 2012-03-01
ATE386737T1 (de) 2008-03-15
DE102004020186A1 (de) 2005-11-17
KR20070007346A (ko) 2007-01-15
UY28868A1 (es) 2005-11-30
WO2005105781A1 (de) 2005-11-10
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
EP1864979B1 (de) 2011-09-07
PE20060172A1 (es) 2006-03-31
EP1740569A1 (de) 2007-01-10

Similar Documents

Publication Publication Date Title
AU2005238144B2 (en) Imidazole derivatives used as TAFIa inhibitors
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
WO2003013526A1 (en) Anticoagulant compounds
WO2002060894A2 (en) Sulfonamide lactam inhibitors of factor xa
US8710232B2 (en) Imidazole derivatives used as TAFIa inhibitors
MX2010012793A (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
DK2104497T3 (en) SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
JP4608495B2 (ja) 第Xa因子阻害剤としてのトリアゾール誘導体
JP4504820B2 (ja) Xa因子阻害剤としてのイミダゾール誘導体
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
MXPA06011067A (en) Imidazole derivatives used as tafia inhibitors
HK1101823B (en) Imidazole derivatives used as tafia inhibitors
AU2002248391A1 (en) Sulfonamide lactam inhibitors of factor XA
HK1117157A1 (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors
HK1117157B (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors
KR20060136457A (ko) 인자 Xa 억제제로서의 피롤-유도체
JPWO2000078747A1 (ja) アシルヒドラジン誘導体、その製造法及び用途

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed